Why Is TWIST BIOSCIENCE COR (TWST) Stock Down Today?

TWST stock fell 6.60% to $155.96 in early trading on Monday, marking a sharp reversal after the biotech firm had reached a 52-week high just days earlier. The decline followed a -2.0% opening gap and a steady drop through the session. The move comes amid mixed analyst coverage and recent insider selling, despite several brokerages having raised price targets for the stock in recent weeks.

What Happened

The stock opened at $163.65, a $3.32 drop from the previous close, and quickly moved lower throughout the session. By 9:30 AM ET, it had fallen to $154.62, its lowest level of the day. The decline came despite recent analyst upgrades, including a $215 price target from Barclays and $190 from Leerink Partners. However, the stock had already fallen -12.7% in a previous session, raising concerns among investors. The drop on Monday appears to reflect broader market sentiment and ongoing pressure from heavy insider selling, with three executives reporting sales totaling $118.9 million in the past 90 days.

What The Data Shows

The stock has traded between $23.30 and $219.71 over the past 52 weeks, with a current market cap of $12.9 billion. Despite a 19.2% year-to-date revenue increase, the company remains unprofitable, with a trailing 12-month net margin of -31.7%. The recent session saw 0.9 million shares traded, which is 0.4 times the 3-month average. The stock has declined -9.2% over the last 8 sessions, from $183.79 to $166.97. Meanwhile, the 30-day average sentiment score has fallen to 49 from 57, indicating deteriorating investor confidence.

What To Watch

The stock is currently without scheduled earnings, but coverage breadth and analyst price target changes will remain key to watch. Investors should monitor further insider activity and whether the recent analyst upgrades translate into renewed buying interest.